The use of TNF-α antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature review

Lucas Armange,Adèle Lacroix,Paul Petitgas,Cédric Arvieux,Caroline Piau-Couapel,Patrice Poubeau,Matthieu Revest,Pierre Tattevin

DOI: https://doi.org/10.1007/s10096-023-04564-2

2023-02-18

Abstract:Paradoxical reaction (PR) and immune reconstitution inflammatory syndrome (IRIS) are common complications of tuberculosis treatment. Corticosteroids are first-line treatment for severe PR or IRIS, particularly neurological. We report four cases of severe PR or IRIS during tuberculosis treatment who required TNF-α antagonists, and identified 20 additional cases through literature review. They were 14 women and 10 men, with a median age of 36 years (interquartile range, 28–52). Twelve were immunocompromised before tuberculosis: untreated HIV infection ( n =6), or immunosuppressive treatment (TNF-α antagonists, n =5; tacrolimus, n =1). Tuberculosis was mostly neuromeningeal ( n =15), pulmonary ( n =10), lymph node ( n =6), and miliary ( n =6), multi-susceptible in 23 cases. PR or IRIS started after a median time of 6 weeks (IQR, 4–9) following anti-tuberculosis treatment start, and consisted primarily of tuberculomas ( n =11), cerebral vasculitis ( n =8), and lymphadenitis ( n =6). First-line treatment of PR or IRIS was high-dose corticosteroids in 23 cases. TNF-α antagonists were used as salvage treatment in all cases, with infliximab ( n =17), thalidomide ( n =6), and adalimumab ( n =3). All patients improved, but 6 had neurological sequelae, and 4 had TNF-α antagonist-related severe adverse events. TNF-α antagonists are safe and effective as salvage or corticosteroid-sparing therapeutic for severe PR or IRIS during tuberculosis treatment.

infectious diseases,microbiology